Autosomal Recessive Nonsyndromic Hearing Loss 104 (DFNB104) — Comprehensive Research Report

1. Disease Information

Overview: Autosomal Recessive Nonsyndromic Hearing Loss 104 (DFNB104), also designated Deafness, Autosomal Recessive 104, is a form of prelingual, congenital, profound sensorineural hearing loss caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in RIPOR2 (formerly known as FAM65B), located on chromosome 6p22.3. The disorder was first mapped and the causal gene identified in 2014 by Diaz-Horta and colleagues in a large consanguineous Turkish kindred (Diaz-Horta et al. 2014, PNAS, PMID 24958875). RIPOR2 encodes a plasma-membrane-associated actin-cytoskeletal regulatory protein that localizes to the base of the stereocilia in cochlear (and vestibular) hair cells and is required for normal stereocilia bundle structure and maintenance.

Key Identifiers: - OMIM: #616515 (DFNB104); gene entry 611410 (RIPOR2) (OMIM 616515; OMIM 611410) - MONDO: MONDO:0014675 - MedGen (NCBI): C4225298 — "Autosomal recessive nonsyndromic hearing loss 104" (MedGen) - HGNC: HGNC:13872 (RIPOR2; formerly FAM65B) - Gene locus: 6p22.3 - Orphanet: Grouped under the generic "Autosomal recessive non-syndromic sensorineural deafness type DFNB" umbrella entries; a DFNB104-specific ORPHA code was not independently confirmed in primary Orphanet sources during this research and should be verified directly against Orphadata before citation. - ICD-10:* H90.3 (Sensorineural hearing loss, bilateral) — generic code; no disease-specific ICD-10/11 code exists for DFNB104.

Synonyms/Alternative Names: - DFNB104 - Deafness, Autosomal Recessive 104 - FAM65B-related deafness - RIPOR2-related nonsyndromic hearing loss (recessive form; distinct from the dominant RIPOR2-related DFNA21)

Data source note: All published information derives from aggregated disease-level resources — pedigree/cosegregation studies in a small number of consanguineous families (Turkish, Tunisian) — plus complementary murine and zebrafish model data, rather than large EHR-derived cohorts. This is consistent with an ultra-rare monogenic recessive deafness gene.

Important nomenclature distinction: RIPOR2 causes two clinically and genetically distinct hearing-loss entities: - DFNB104 — biallelic (recessive) loss-of-function variants → congenital, profound, non-progressive hearing loss (this report's focus). - DFNA21 — heterozygous, dominant-negative in-frame deletion (c.1696_1707del) → adult-onset, progressive hearing loss, described as a frequent Dutch founder variant (Oonk et al. 2020, PMID 32631815).

2. Etiology

Disease Causal Factors: DFNB104 is purely genetic/monogenic — caused by biallelic loss-of-function (null or severely hypomorphic) variants in RIPOR2. No environmental, infectious, or multifactorial contribution has been reported.

Genetic Risk Factors: - Causal variants identified to date (small number of families): - c.102-1G>A (splice acceptor, intron 2) — homozygous in the original consanguineous Turkish family, causing in-frame skipping of exon 3 and deletion of residues 34–86 (p.R34_D86delinsS) within the core PX membrane-localization domain (Diaz-Horta et al. 2014, PMID 24958875). - c.189-1G>A (splice acceptor variant) — reported in ClinVar as pathogenic for DFNB104 (ClinVar RCV000190353). - c.1561C>T (p.Arg521) — homozygous nonsense variant identified in three Tunisian siblings with congenital profound hearing loss and* vestibular areflexia, the third reported RIPOR2 pathogenic allele and the first with a documented vestibular phenotype (Morel et al. 2023, Clinical Genetics, DOI 10.1111/cge.14436). - Consanguinity is a strong risk factor for exposing biallelic RIPOR2 variants, consistent with the Turkish and Tunisian consanguineous pedigrees in which the condition has been reported. - The mutation was absent from dbSNP, the Exome Variant Server, and 330 Turkish population controls in the original report, consistent with a rare, family-restricted (non-founder) allele in that population — in contrast to the common Dutch dominant founder deletion causing DFNA21.

Environmental Risk Factors: None identified; this is a purely Mendelian condition with no reported environmental modifiers of penetrance.

Protective Factors: None reported specific to RIPOR2/DFNB104. Speculative genetic compensation by paralogs RIPOR1 and RIPOR3 (~70% sequence similarity) has been proposed as a possible explanation for milder or absent vestibular phenotypes in some model systems, but this has not been demonstrated as a true protective mechanism in humans (Morel et al. 2023).

Gene-Environment Interactions: None documented; no CTD or GxE database entries were identified linking RIPOR2 to environmental modifiers.

3. Phenotypes

Auditory phenotype (core feature)

• Type: Clinical sign / sensory (audiometric) abnormality.
• Onset: Congenital / prelingual — hearing loss is present from birth.
• Severity: Profound, and in the founding Turkish family, symmetric across affected individuals.
• Progression: Notably non-progressive — "available audiograms did not suggest progression of the hearing loss" in the original family, distinguishing DFNB104 from many other DFNB forms and from the dominant DFNA21 (which is progressive).
• Frequency: All 6 affected individuals in the index Turkish kindred; all 3 affected siblings in the Tunisian kindred — i.e., fully penetrant in reported biallelic carriers.
• Suggested HPO terms:
• HP:0001739 Sensorineural hearing impairment
• HP:0008625 Bilateral sensorineural hearing impairment
• HP:0000456 Prelingual sensorineural hearing impairment (or the more general HP:0008527 congenital sensorineural hearing impairment)
• HP:0001737 Profound sensorineural hearing impairment (if distinguishing profound severity)

Audiological test findings

• Absent otoacoustic emissions (OAEs) — HP:0025400 or descriptor "absent OAEs" (no dedicated HPO term; document as laboratory abnormality).
• Absent/abnormal acoustic reflexes.
• Absent/abnormal auditory brainstem responses (ABR).

Vestibular phenotype (variant-dependent, not uniform)

• The original Turkish family: normal vestibular function — negative Romberg test, normal tandem gait, no balance complaints ("None had balance problems").
• The Tunisian family (p.Arg521 nonsense variant): vestibular areflexia*, delayed independent walking (21–24 months), abnormal cervical VEMPs, and abnormal video head-impulse testing showing negative gains and covert saccades on posterior and lateral semicircular canals (Morel et al. 2023).
• This indicates variable expressivity/phenotypic heterogeneity across RIPOR2 alleles — possibly allele-specific (nonsense/truncating vs. splice-site) or genetic-background-dependent.
• Suggested HPO terms:
• HP:0000763 or HP:0002321 Vertigo / Vestibular dysfunction
• HP:0002321 Vestibular areflexia (if a specific term is used) — verify exact HPO ID at curation time
• HP:0001270 Motor delay (for delayed walking, if attributable)

Quality of life impact

No dedicated EQ-5D/SF-36/disease-specific QOL studies were identified for DFNB104 specifically. As with other forms of congenital profound sensorineural deafness, the expected impact includes impaired spoken-language acquisition without early intervention (hearing aids/cochlear implantation), and — in the vestibular-areflexia subset — additional impact on gross motor development and balance-dependent activities (data extrapolated from general profound-deafness and vestibular-areflexia literature; no RIPOR2-specific QOL instrument data located).

4. Genetic/Molecular Information

Causal Gene: RIPOR2 (RHO Family Interacting Cell Polarization Regulator 2), formerly FAM65B. - HGNC: HGNC:13872 - OMIM gene: 611410 - Locus: 6p22.3 - Ensembl:* ENSG00000111913

Pathogenic Variants (recessive, DFNB104): | Variant | Effect | Family/Population | Source | |---|---|---|---| | c.102-1G>A | Splice acceptor → exon 3 skipping, in-frame deletion of aa 34-86 (p.R34_D86delinsS), disrupting the PX membrane-localization domain | Consanguineous Turkish family (6 affected) | PMID 24958875 | | c.189-1G>A | Splice acceptor variant, pathogenic | ClinVar-reported | ClinVar RCV000190353 | | c.1561C>T (p.Arg521*) | Nonsense/premature stop, exon 14 | Consanguineous Tunisian family (3 affected siblings) | Morel et al. 2023, Clin Genet |

• Variant classification (ACMG/AMP): All reported variants classified pathogenic per cosegregation with disease, absence from population databases/controls, and functional evidence of protein mislocalization (for the splice variant).
• Variant type/class: Splice-site (2 variants) and nonsense (1 variant) — all predicted/demonstrated loss-of-function, consistent with a haploinsufficiency-independent, biallelic-null recessive mechanism (contrasting with the dominant-negative in-frame deletion causing DFNA21).
• Allele frequency: The recessive DFNB104 alleles are private/family-restricted and were absent from gnomAD/ExAC/dbSNP-scale population databases at the time of reporting — consistent with ultra-rare recessive alleles rather than founder variants (unlike the DFNA21 c.1696_1707del founder deletion, common in the Dutch population).
• Somatic vs. germline: Germline only; no somatic RIPOR2 hearing-loss association reported.
• Functional consequence: Loss of function — the mutant protein (from the splice variant) accumulates in cytoplasmic inclusion bodies and fails to reach the plasma membrane, in contrast to wild-type RIPOR2/FAM65B, which targets the stereocilia plasma membrane (PMID 24958875).
• ClinGen Gene-Disease Validity: RIPOR2 has an Expert Panel "Definitive"/"Strong"-tier classification for autosomal recessive nonsyndromic deafness 104 (reported as ClinGen "Expert Review Green" via PanelApp aggregation).
• Modifier genes: RIPOR1 and RIPOR3 (paralogs, ~70% sequence similarity to RIPOR2) have been proposed as potential functional compensators explaining phenotypic variability (e.g., absence of vestibular phenotype in some carriers/models), though this is hypothesis-generating rather than directly demonstrated in humans.
• Epigenetic information: None reported specific to RIPOR2/DFNB104.
• Chromosomal abnormalities: None reported; DFNB104 is caused by sequence-level variants, not large structural/chromosomal rearrangements.

Protein structure/function: - RIPOR2/FAM65B contains a PX(-like)-BAR module region implicated in membrane targeting and curvature sensing (though a later PNAS letter disputed strict PX-BAR domain classification — PMID for "Little evidence that FAM65B belongs to the family of PX and BAR domain-containing proteins," PNAS 2014 — a caveat worth noting for structural claims). - RIPOR2 is an atypical inhibitor of the small GTPase RhoA, implicated (in non-auditory contexts) in myoblast fusion and leukocyte polarization/migration. - In hair cells, RIPOR2 forms circumferential ring-like oligomeric structures (~229 ± 7 nm diameter) at the basal taper of stereocilia, distinct from taperin's intra-stereociliary core localization; RhoC (not RhoA) co-localizes with and regulates RIPOR2 oligomerization in this compartment (Krey et al. 2016, eLife, PMID for "Murine Fam65b forms ring-like structures..."). - RIPOR2 interacts with MYH9 (a known deafness gene, DFNA17); loss of Ripor2 in mice is associated with reduced MYH9 protein abundance (despite increased transcript) and aberrant kinocilium localization during hair-bundle morphogenesis (Xiong et al. 2018, J Mol Med, PMID 30280293).

Suggested ontology terms: - Gene: hgnc:13872 (RIPOR2) - GO Molecular Function: GO:0005096 (GTPase activator activity) — for RhoA/RhoC-modulating activity; verify precise GO term at curation - GO Cellular Component: GO:0032420 (stereocilium), GO:0060091 (kinocilium) - GO Biological Process: GO:0032420-related stereocilium organization; GO:0060088 auditory receptor cell stereocilium organization

5. Environmental Information

No environmental factors, lifestyle factors, or infectious agents have been implicated in DFNB104 causation — it is a fully penetrant monogenic recessive disorder. No CTD, TOXNET, or epidemiological database entries link RIPOR2/DFNB104 to environmental exposures.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger: Biallelic loss-of-function RIPOR2 variants (splice-site or nonsense) → absent or non-functional RIPOR2 protein, or protein that fails to reach its normal subcellular destination (mutant protein retained in cytoplasmic inclusion bodies rather than trafficking to the plasma membrane) — PMID 24958875.
2. Subcellular/structural consequence: Loss of the RIPOR2 circumferential ring structure at the base of stereocilia (normally regulated by RhoC-dependent oligomerization) — PMID for Krey et al. 2016 eLife.
3. Cytoskeletal/interactome consequence: Disrupted interaction with MYH9 (myosin heavy chain 9), reduced MYH9 protein levels in the cochlea, and mislocalization of the kinocilium during hair-bundle morphogenesis — PMID 30280293.
4. Cellular/organelle consequence: Abnormal stereociliary bundle structure and orientation; in mouse models, this manifests as disorganized, misoriented hair bundles from early development (structural/developmental defect) rather than a purely late, degenerative process — PMID 30280293; complementary evidence from the paralogous EPS8L2/DFNB106 pathway shows a distinct maintenance-phase mechanism (see note below).
5. Functional consequence: Impaired mechanotransduction — reduced mechanotransduction currents in RIPOR2-deficient hair cells, with re-expression rescue demonstrated experimentally (eLife 2016), directly linking RIPOR2 loss to sensory transduction failure rather than only structural malformation.
6. Clinical manifestation: Congenital, profound, non-progressive sensorineural hearing loss (± vestibular areflexia in some allelic variants).

Note on module conformance (dismech context): This causal chain — stereociliary actin-cytoskeleton disruption → hair-bundle structural/mechanotransduction failure → profound congenital deafness — is mechanistically analogous to, but molecularly distinct from, the EPS8/EPS8L2 (DFNB102/DFNB106) pathway, which involves stereocilia elongation and maintenance via direct actin-bundling rather than RhoA/RhoC-regulated membrane-ring formation. If a "stereocilia structure/maintenance" mechanism module exists in dismech, DFNB104 nodes should specify the RIPOR2/RhoC/MYH9 axis distinctly from the EPS8/EPS8L2/actin-elongation axis.

Cellular processes involved: - Actin cytoskeleton organization/regulation (via Rho-family GTPase signaling) - Stereocilia bundle morphogenesis and maintenance - Mechanotransduction (sensory transduction in hair cells) - Possibly cell polarity establishment (kinocilium positioning)

Protein dysfunction: Loss of function via (a) failed membrane trafficking/localization (splice variant) or (b) truncation/nonsense-mediated decay (nonsense variant) — net effect is absence of functional RIPOR2 at the stereociliary base.

Biochemical abnormalities: Reduced MYH9 protein abundance despite normal/increased Myh9 transcript levels in Ripor2-null mouse cochlea — a post-transcriptional/protein-stability defect downstream of RIPOR2 loss.

Molecular profiling: No transcriptomic, proteomic, metabolomic, or single-cell/spatial datasets specific to human DFNB104 tissue were identified (expected, given the rarity of the condition and inaccessibility of human inner-ear tissue); mechanistic molecular data derive from mouse and zebrafish models.

Suggested GO terms: - GO:0060088 — auditory receptor cell stereocilium organization - GO:0035090 — maintenance of apical/basal cell polarity (if applicable to kinocilium positioning) - GO:0007266 — Rho protein signal transduction

Suggested CL terms: - CL:0000601 — inner hair cell - CL:0000602 — outer hair cell - CL:0000855 — sensory hair cell (general, if subtype not specified)

7. Anatomical Structures Affected

Organ level: - Primary organ: inner ear (cochlea) — auditory portion. - Secondary/variant-dependent involvement: vestibular labyrinth (semicircular canals, otolith organs) — affected in the Tunisian p.Arg521* family but not the original Turkish splice-variant family, indicating allele-dependent penetrance of the vestibular phenotype. - Body system: sensory/auditory-vestibular system (cranial nerve VIII pathway secondarily, via sensory input loss, not primary neuronal pathology).

Tissue and cell level: - Sensory epithelium of the organ of Corti (cochlea) — inner and outer hair cells (CL:0000601, CL:0000602). - Vestibular sensory epithelium (cristae ampullares, maculae) in variant-affected individuals.

Subcellular level: - Stereocilia — specifically the basal taper/base region where RIPOR2 forms its ring-like oligomeric structure (distinct from the stereocilia tips, where EPS8/EPS8L2 act). - Plasma membrane (site of normal RIPOR2 localization; site of failed trafficking for the mutant splice-variant protein). - Cytoplasmic inclusion bodies (site of pathological mutant-protein accumulation). - Kinocilium (secondarily mislocalized in Ripor2-deficient mice).

Localization: - Bilateral, symmetric involvement of both ears (consistent across all reported human cases). - No lateralization/asymmetry reported.

Suggested UBERON terms: - UBERON:0001846 — cochlea - UBERON:0002106 — spiral organ (organ of Corti) - UBERON:0002418 — stereocilium bundle / UBERON:0009866 stereocilium (verify precise term) - UBERON:0001838 — vestibular apparatus (for the variant-associated phenotype)

Suggested GO Cellular Component terms: - GO:0032420 — stereocilium - GO:0005886 — plasma membrane

8. Temporal Development

Onset: Congenital/prelingual — hearing loss is present from birth or the earliest testable age (universal newborn hearing screening range), consistent with a developmental/structural stereociliary defect rather than a late degenerative process.

Onset pattern: Not acute or insidious in the usual sense — it is a static congenital deficit.

Progression: - Auditory phenotype: Non-progressive in the original (splice-variant) family — audiograms performed at multiple ages did not show worsening. This is a notable point of contrast with the RIPOR2-associated dominant DFNA21, which is explicitly progressive with average onset age 30.6 years (range 0–70 years) in the Dutch founder-variant cohort (PMID 32631815). - Vestibular phenotype (where present): Static congenital areflexia with developmental consequence (delayed independent walking at 21–24 months in the Tunisian siblings) rather than progressive vestibular decline.

Disease course pattern: Stable, chronic, lifelong sensorineural hearing loss.

Disease stages: Not formally staged (unlike some progressive conditions); severity is described simply as profound at diagnosis and remains profound.

Remission patterns: None — this is a structural/developmental sensory deficit with no spontaneous remission; management is via habilitation (hearing aids, cochlear implantation), not disease-modifying treatment.

Critical periods: As with all forms of prelingual profound deafness, early identification (newborn hearing screening) and early intervention (hearing aids/cochlear implant, before ~2–3 years of age) represent the critical window for optimizing spoken-language outcomes — a general principle for congenital SNHL, not RIPOR2-specific data.

9. Inheritance and Population

Epidemiology: - No population-level prevalence or incidence estimates exist for DFNB104 specifically; it is described only via individual case families (an ultra-rare, "cases in literature" level of epidemiological documentation — likely fewer than 10 families reported worldwide as of 2023–2024: 1 Turkish family with 6 affected, 1 Tunisian family with 3 affected, plus scattered additional ClinVar-reported variants of uncertain full clinical documentation). - Suggested prevalence_class: NOT_YET_DOCUMENTED or CASES_IN_LITERATURE (per dismech's PrevalenceMeasureEnum), given the case-family-level evidence base.

Inheritance pattern: Autosomal recessive (biallelic variants required; heterozygous carriers are unaffected for DFNB104, in contrast to the dominant DFNA21 allele in the same gene).

Penetrance: Complete in all reported biallelic carriers (100% penetrance for the auditory phenotype across both reported families).

Expressivity: Variable — specifically regarding the vestibular component (present in the Tunisian p.Arg521* family, absent in the Turkish c.102-1G>A family), suggesting possible allele-specific or genetic-background-dependent expressivity. The auditory phenotype (profound, congenital, non-progressive) appears consistent across families.

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not reported in the literature reviewed.

Founder effects: Not established for the recessive DFNB104 alleles (each reported variant appears private to its family) — this contrasts with the well-characterized Dutch founder deletion causing the dominant DFNA21.

Consanguinity role: Central — both reported families (Turkish, Tunisian) are consanguineous, which is the mechanism by which rare private recessive alleles became biallelic and phenotypically manifest.

Carrier frequency: Not established in population databases (gnomAD) given the rarity/private nature of reported alleles.

Population demographics: - Reported affected families: Turkish (original discovery family) and Tunisian (second reported vestibular-affected family) — both from populations with documented elevated rates of consanguineous marriage, consistent with ascertainment bias toward populations where recessive conditions are more readily unmasked and studied. - No broader geographic/ethnic prevalence data available. - Sex ratio: Autosomal recessive — expected 1:1 male:female; no skew reported (consistent with the 6 and 3 affected individuals reported, though gender breakdown was not the emphasized detail in these papers).

10. Diagnostics

Clinical/audiological tests: - Auditory brainstem response (ABR): absent, consistent with profound SNHL. - Otoacoustic emissions (OAE): absent/negative. - Acoustic reflex testing: absent. - Pure-tone audiometry: profound bilateral symmetric SNHL. - Vestibular testing (where indicated): cervical VEMPs (abnormal in Tunisian family), video head-impulse test (vHIT) — negative gains, covert saccades on posterior/lateral canals in the vestibular-areflexia subgroup.

Genetic testing: - Recommended approach: Given DFNB104's genetic and phenotypic overlap with dozens of other DFNB loci (e.g., GJB2, MYO15A, OTOF, and the mechanistically related EPS8/EPS8L2/DFNB102/106), a multi-gene nonsyndromic hearing loss panel or exome sequencing (especially in consanguineous families, where autozygosity mapping/homozygosity-region analysis is powerful — as used in both the original Turkish and Tunisian discovery studies) is the standard diagnostic approach rather than single-gene RIPOR2 testing. - Whole exome sequencing (WES): Was the discovery method in both published families (combined with linkage/homozygosity mapping). - Gene panels: RIPOR2 is included in clinical "monogenic hearing loss" gene panels (e.g., Genomics England PanelApp lists RIPOR2 under its Monogenic hearing loss panel). - Chromosomal microarray/karyotyping/FISH: Not applicable — DFNB104 arises from sequence-level (not structural chromosomal) variants. - Mitochondrial DNA testing: Not applicable (nuclear gene).

Clinical criteria: No RIPOR2/DFNB104-specific diagnostic criteria exist beyond standard nonsyndromic hearing loss workup; diagnosis is genetically confirmed (biallelic pathogenic RIPOR2 variants in a proband with congenital nonsyndromic profound SNHL, especially with consanguinity or homozygosity by descent).

Differential diagnosis: - Other DFNB loci causing congenital profound nonsyndromic SNHL (GJB2/DFNB1, MYO15A/DFNB3, OTOF/DFNB9, TMC1/DFNB7/11, and many others). - Usher syndrome (if vestibular areflexia is present in an affected individual — must be distinguished from RP-associated Usher syndrome by absence of retinal/ophthalmologic findings, since the Tunisian RIPOR2 phenotype mimics a Usher-like cochleovestibular presentation without retinitis pigmentosa). - The mechanistically related but molecularly distinct EPS8-family disorders (DFNB102/EPS8, DFNB106/EPS8L2) — clinically distinguishable by their typically progressive (rather than congenital-stable) course.

Screening: Universal newborn hearing screening (standard of care generally, not RIPOR2-specific) would detect the congenital profound hearing loss; cascade genetic testing/carrier screening is relevant in consanguineous families with a known proband variant.

11. Outcome/Prognosis

Survival/mortality: No excess mortality — DFNB104 is an isolated (nonsyndromic) sensory disorder with no reported systemic or life-limiting comorbidity.

Morbidity/function: - Primary morbidity is profound congenital deafness, with attendant impact on spoken-language development if unaddressed by early habilitation. - In the vestibular-areflexia subset (Tunisian family), additional morbidity includes delayed gross motor/balance milestones (delayed independent walking) and likely lifelong absence of the vestibulo-ocular reflex, which may affect balance in low-visual/proprioceptive-input conditions (e.g., darkness, uneven surfaces) — extrapolated from general vestibular-areflexia literature, not RIPOR2-specific outcome studies.

Disease course: Stable — the hearing loss does not progress further once established (a favorable prognostic feature relative to progressive DFNB/DFNA forms), meaning habilitative interventions (hearing aids, cochlear implants) are not expected to need escalation due to further hearing decline.

Complications: None specific reported beyond the sensory/developmental consequences above; cochlear implantation is expected to be effective given the absence of documented cochlear structural malformation beyond the stereociliary/hair-cell level (though implant-specific outcome data for RIPOR2/DFNB104 patients specifically were not identified in this search).

Prognostic factors: Early cochlear implantation/hearing amplification is the major modifiable prognostic factor for language outcomes, per general principles of congenital profound SNHL management (not RIPOR2-specific trial data).

12. Treatment

No RIPOR2/DFNB104-specific gene therapy, pharmacotherapy, or targeted molecular treatment currently exists or is in registered clinical trials (no ClinicalTrials.gov entries or AAV inner-ear gene-therapy programs targeting RIPOR2 were identified in this search, in contrast to genes like OTOF, which has advanced AAV gene-therapy programs).

Standard of care (supportive/rehabilitative, non-gene-specific): - Hearing amplification: Hearing aids for residual hearing (typically limited benefit given profound loss). - NCIT term: NCIT:C15302 (Physical Therapy) is not correct; more appropriate would be a hearing-device/audiologic-rehabilitation NCIT term if available, or leave treatment_term free-text if no exact NCIT match exists (device-based interventions currently lack a precise NCIT clinical-action term per dismech's own documented gap for "DEVICE" modality). - Cochlear implantation: The mainstay definitive intervention for congenital profound bilateral SNHL. - NCIT: no exact single term found in this search; consider NCIT:C15329 (Surgical Procedure) as the treatment_term with device/implant specified in description, or search NCIT specifically for "Cochlear Implantation" at curation time. - Vestibular rehabilitation (for the vestibular-areflexia subgroup): standard balance/vestibular physical therapy. - NCIT:C15302 (Physical Therapy) applicable here. - Genetic counseling: Recommended for consanguineous families with an identified proband, given the autosomal recessive inheritance and elevated recurrence risk (25% per pregnancy for carrier parents). - NCIT:C15240 (Genetic Counseling).

Experimental/preclinical therapeutic direction (mechanistic rationale, not yet RIPOR2-specific): - Mouse model rescue experiments have shown that re-expression of Fam65b/Ripor2 in deficient hair cells can rescue mechanotransduction defects (Krey et al. 2016, eLife), providing proof-of-concept rationale for a future AAV-mediated gene-replacement approach analogous to those in advanced development for OTOF, TMC1, and other DFNB genes — but no RIPOR2-specific vector or preclinical inner-ear gene-therapy publication was identified as of this search.

Treatment outcomes: No RIPOR2-specific treatment-response, adverse-event, or comparative-effectiveness data located.

13. Prevention

• Primary prevention: Not applicable in the traditional sense (monogenic disorder); the only "prevention" avenue is reproductive genetic counseling and reduction of consanguineous-union recurrence risk awareness in affected families.
• Secondary prevention/early detection: Universal newborn hearing screening (general standard of care, not RIPOR2-specific) enables early diagnosis and prompt habilitative intervention.
• Genetic screening: Carrier screening and prenatal/preimplantation genetic diagnosis (PGD) are options for known-carrier consanguineous families once a familial RIPOR2 variant is identified, per standard ACMG-style recessive-disorder counseling principles.
• Tertiary prevention: Early cochlear implantation/amplification to prevent language-developmental complications of unaddressed profound deafness; vestibular rehabilitation to mitigate balance-related complications in the vestibular-areflexia subgroup.
• Public health/behavioral/immunization/prophylaxis: Not applicable — no infectious, immunizable, or behavioral risk-modification component to this monogenic disorder.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring RIPOR2-associated hearing loss has been reported in companion animals or wildlife (no OMIA entry identified in this search) — all non-human data derive from engineered/induced models (see Section 15), not spontaneous natural disease.
• Comparative biology: The RIPOR2 gene and its role in stereociliary actin regulation appear evolutionarily conserved (functional orthologs studied in mouse and zebrafish), and the RhoC-RIPOR2-MYH9 interaction network appears conserved across these model systems, though the notable species discrepancy in vestibular phenotype (human vestibular areflexia in some RIPOR2-null patients vs. normal vestibular function in Ripor2-knockout mice and zebrafish) is a documented cross-species divergence meriting explicit note (Morel et al. 2023) — a candidate HUMAN_MODEL_MISMATCH discussion for dismech curation.
• Zoonotic/transmission relevance: Not applicable (non-infectious monogenic disorder).

15. Model Organisms

Mouse models: - Ripor2 (Fam65b) knockout mice: Complete deafness; hair bundle morphological defects (disorganized/misoriented stereocilia bundles), reduced mechanotransduction currents, aberrant kinocilium localization, and reduced MYH9 protein abundance in the cochlea (Xiong et al. 2018, J Mol Med, PMID 30280293; Krey et al. 2016, eLife). - Phenotype recapitulation: High fidelity for the auditory phenotype (deafness, hair-bundle/stereocilia structural defects, mechanotransduction failure) — closely mirrors human DFNB104. - Model limitation: Vestibular phenotype is NOT recapitulated — Ripor2-knockout mice show normal balance/vestibular function (no circling behavior), unlike the vestibular areflexia documented in at least one human family. This is an explicit, well-documented human-model mismatch meriting HUMAN_MODEL_MISMATCH classification (per dismech schema conventions) rather than a generic KNOWLEDGE_GAP, since the evidence (mouse vestibular testing) exists but its translational validity to the human vestibular phenotype is the open question. Proposed explanations in the primary literature include incomplete/insensitive vestibular testing in mice and genetic compensation by paralogs RIPOR1/RIPOR3. - Rescue experiments: Re-expression of wild-type Fam65b/Ripor2 in deficient hair cells rescues mechanotransduction current defects, demonstrating causality and supporting the eventual therapeutic feasibility of gene replacement (eLife 2016).

Zebrafish models: - fam65b knockdown (morpholino) zebrafish: Significant reduction in saccular hair cell numbers and neuromasts, and hearing loss, reported in the original discovery paper (Diaz-Horta et al. 2014, PMID 24958875). - fam65b nonsense-mutant zebrafish (from the Tunisian-family follow-up study): No circling behavior or balance abnormality at 5 days post-fertilization, again showing the auditory-but-not-vestibular phenotype discrepancy relative to at least one human RIPOR2 family (Morel et al. 2023).

Applications: These models have been used to establish causality (loss-of-function → hearing loss), define the subcellular localization and oligomeric ring structure of RIPOR2 at the stereociliary base, dissect the RhoC-dependent regulatory mechanism, identify the MYH9 interaction, and demonstrate rescue of mechanotransduction by gene re-expression — the last providing direct preclinical proof-of-concept for a future gene-therapy approach.

Resources: MGI (Mouse Genome Informatics) for Ripor2 knockout allele records; ZFIN for zebrafish fam65b/ripor2 mutant/morphant lines (specific allele/stock IDs not retrieved in this search — recommend direct MGI/ZFIN query at curation time for exact resource identifiers).

Summary of Key Evidence Citations

Notable curation caveats for dismech entry construction: 1. The Orphanet-specific identifier for DFNB104 could not be independently confirmed in this research pass and should be verified directly against Orphadata/ORPHA before citation (avoid citing an unverified ORPHA code). 2. The PX-BAR domain structural classification for RIPOR2/FAM65B has been directly disputed in the literature (PNAS 2014 technical comment) — cite this nuance if describing protein domain structure in detail. 3. The vestibular phenotype is not uniform across reported DFNB104 families — this is a genuine expressivity finding, not an error, and should be modeled as such (e.g., via subtype-level or evidence-item-level distinction between the Turkish and Tunisian families) rather than collapsed into a single uniform phenotype claim. 4. No RIPOR2-specific prevalence, treatment-trial, or QOL data exist beyond the two published case families — this is an ultra-rare, "cases-in-literature" level disorder, and prevalence/epidemiology fields should be populated conservatively (e.g., CASES_IN_LITERATURE / NOT_YET_DOCUMENTED).